These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37087697)

  • 1. Inhaled levodopa for threatening impending OFF episodes in managing Parkinson's disease.
    Jost WH; Kulisevsky J; LeWitt PA
    J Neural Transm (Vienna); 2023 Jun; 130(6):821-826. PubMed ID: 37087697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Clinical Development of Levodopa Inhalation Powder.
    Hauser RA; LeWitt PA; Waters CH; Grosset DG; Blank B
    Clin Neuropharmacol; 2023 Mar-Apr 01; 46(2):66-78. PubMed ID: 36715241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa Inhalation Powder: A Review in Parkinson's Disease.
    Paik J
    Drugs; 2020 Jun; 80(8):821-828. PubMed ID: 32319076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease.
    Safirstein BE; Ellenbogen A; Zhao P; Henney HR; Kegler-Ebo DM; Oh C
    Clin Ther; 2020 Jun; 42(6):1034-1046. PubMed ID: 32482490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease.
    Lipp MM; Batycky R; Moore J; Leinonen M; Freed MI
    Sci Transl Med; 2016 Oct; 8(360):360ra136. PubMed ID: 27733560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CVT-301 for the treatment of Parkinson's disease.
    Shpiner DS; Bette S; Di Luca DG; Margolesky J
    Expert Rev Neurother; 2019 Jul; 19(7):603-611. PubMed ID: 31104518
    [No Abstract]   [Full Text] [Related]  

  • 8. A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease.
    Farbman ES; Waters CH; LeWitt PA; Rudzińska M; Klingler M; Lee A; Qian J; Oh C; Hauser RA
    Parkinsonism Relat Disord; 2020 Dec; 81():144-150. PubMed ID: 33130477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes.
    Thach A; Zichlin ML; Kirson N; Yang K; Gaburo K; Pappert E; Mehta D; Williams GR
    J Comp Eff Res; 2022 Mar; 11(4):285-295. PubMed ID: 35068168
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study.
    Grosset DG; Dhall R; Gurevich T; Kassubek J; Poewe WH; Rascol O; Rudzinska M; Cormier J; Sedkov A; Oh C
    Parkinsonism Relat Disord; 2020 Feb; 71():4-10. PubMed ID: 31927343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.
    LeWitt PA; Hauser RA; Grosset DG; Stocchi F; Saint-Hilaire MH; Ellenbogen A; Leinonen M; Hampson NB; DeFeo-Fraulini T; Freed MI; Kieburtz KD
    Mov Disord; 2016 Sep; 31(9):1356-65. PubMed ID: 27090868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's disease.
    Stocchi F; Vacca L; Stirpe P; Torti M
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1189-1195. PubMed ID: 30479171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease.
    Hauser RA; Isaacson SH; Ellenbogen A; Safirstein BE; Truong DD; Komjathy SF; Kegler-Ebo DM; Zhao P; Oh C
    Parkinsonism Relat Disord; 2019 Jul; 64():175-180. PubMed ID: 30992235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease.
    Simões RM; Castro Caldas A; Ferreira JJ
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):85-101. PubMed ID: 32011195
    [No Abstract]   [Full Text] [Related]  

  • 15. A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson's disease.
    Lipp MM; Hickey AJ; Langer R; LeWitt PA
    Expert Opin Drug Deliv; 2021 Nov; 18(11):1559-1569. PubMed ID: 34311641
    [No Abstract]   [Full Text] [Related]  

  • 16. On-Demand Therapy for OFF Episodes in Parkinson's Disease.
    Olanow CW; Poewe W; Rascol O; Stocchi F
    Mov Disord; 2021 Oct; 36(10):2244-2253. PubMed ID: 34363424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson's disease.
    Stocchi F; Vacca L; Grassi A; Torti M
    Expert Opin Pharmacother; 2021 Jun; 22(8):965-972. PubMed ID: 33629617
    [No Abstract]   [Full Text] [Related]  

  • 18. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled levodopa (Inbrija) for Parkinson's disease.
    Med Lett Drugs Ther; 2019 May; 61(1572):73-74. PubMed ID: 31169799
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.